Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026
Immunic, Inc. (IMUX) will host a virtual R&D Day on November 5, 2026, to discuss progressive multiple sclerosis (MS) and its lead asset, vidofludimus calcium (IMU-838). The company plans to initiate a Phase 3 trial for progressive MS later in 2026, highlighting the asset's potential neuroprotective effects.
How this was made

The 30-second read
Why it matters
The R&D Day serves as a platform to detail the upcoming trial, which may attract analyst coverage and modest investor interest, but no immediate financial impact is expected.
Market read
A forward‑looking corporate event that introduces a new clinical trial timeline, offering a low‑to‑moderate trading signal for IMUX.
What to watch
Potential regulatory hurdles, competition from other MS therapies, and the company's cash runway could temper enthusiasm.
Background
Immunic is a late‑stage biotech focused on oral therapies for neurologic diseases. Its lead asset, vidofludimus calcium, is already in Phase 3 for relapsing MS; the company now plans a separate Phase 3 for progressive MS.
Ticker impact
Immunic announced a virtual R&D Day and plans to initiate a Phase 3 progressive MS trial later in 2026, providing the first public disclosure of this upcoming trial.
potential modest upside as investors price in the upcoming Phase 3 trial
No data or results are released yet; the news is a forward‑looking event that may lift sentiment but impact is limited until trial data emerge.
Market effects
Adds a new data point for the biotech/neurology sector, but unlikely to shift broader sector sentiment.
Primarily U.S. biotech investors; limited regional effect.
Minimal global impact beyond niche investors tracking MS therapeutics.
Counterpoint
Investors may view the trial initiation as a delay risk and could stay on the sidelines until data are released.
Key entities
- companyImmunic, Inc.
Nasdaq‑listed biotech developing oral MS therapies (ticker IMUX).
- executiveErik Lundgren
Chief Executive Officer of Immunic.



